1. Home
  2. KALV vs STKL Comparison

KALV vs STKL Comparison

Compare KALV & STKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALV
  • STKL
  • Stock Information
  • Founded
  • KALV N/A
  • STKL 1973
  • Country
  • KALV United States
  • STKL United States
  • Employees
  • KALV N/A
  • STKL N/A
  • Industry
  • KALV Biotechnology: Pharmaceutical Preparations
  • STKL Precious Metals
  • Sector
  • KALV Health Care
  • STKL Basic Materials
  • Exchange
  • KALV Nasdaq
  • STKL Nasdaq
  • Market Cap
  • KALV 796.4M
  • STKL 730.4M
  • IPO Year
  • KALV N/A
  • STKL N/A
  • Fundamental
  • Price
  • KALV $10.95
  • STKL $5.91
  • Analyst Decision
  • KALV Strong Buy
  • STKL Strong Buy
  • Analyst Count
  • KALV 8
  • STKL 2
  • Target Price
  • KALV $26.43
  • STKL $9.50
  • AVG Volume (30 Days)
  • KALV 1.5M
  • STKL 417.5K
  • Earning Date
  • KALV 09-11-2025
  • STKL 11-04-2025
  • Dividend Yield
  • KALV N/A
  • STKL N/A
  • EPS Growth
  • KALV N/A
  • STKL N/A
  • EPS
  • KALV N/A
  • STKL N/A
  • Revenue
  • KALV $1,426,000.00
  • STKL $762,882,000.00
  • Revenue This Year
  • KALV N/A
  • STKL $12.80
  • Revenue Next Year
  • KALV $213.43
  • STKL $7.91
  • P/E Ratio
  • KALV N/A
  • STKL N/A
  • Revenue Growth
  • KALV N/A
  • STKL 11.44
  • 52 Week Low
  • KALV $7.30
  • STKL $3.65
  • 52 Week High
  • KALV $17.28
  • STKL $8.11
  • Technical
  • Relative Strength Index (RSI)
  • KALV 27.85
  • STKL 42.46
  • Support Level
  • KALV $11.93
  • STKL $5.74
  • Resistance Level
  • KALV $12.43
  • STKL $6.15
  • Average True Range (ATR)
  • KALV 0.60
  • STKL 0.18
  • MACD
  • KALV -0.22
  • STKL -0.02
  • Stochastic Oscillator
  • KALV 6.17
  • STKL 22.08

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About STKL SunOpta Inc.

SunOpta Inc is a Canadian company that focuses on a healthy product portfolio. The company is a manufacturer for natural and private label brands and also produces its own propriety brands, including SOWN, Dream and West Life. The core of its product portfolio is a range of plant-based beverages, including oat, almond, soy, coconut and rice milks and creamers, which have a favorable climate profile relative to traditional dairy milks in terms of lower carbon emissions and water usage. Their plant-based offerings include non-genetically modified, organic, and gluten-free products. The consumer products portfolio also includes protein shakes, teas, broths, and fruit snacks. Geographically, the company operates in U.S, Canada and Others, out of which it derives maximum revenue from U.S.

Share on Social Networks: